<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008864</url>
  </required_header>
  <id_info>
    <org_study_id>Senna in Uremic Pruritus</org_study_id>
    <nct_id>NCT02008864</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Senna in Uremic Pruritus</brief_title>
  <official_title>Phase II Study of the Effect of Senna Alexandrina Mill. on Uremic Pruritus and Serum IL-2, INF-δ and TNF-α Levels of Hemodialysed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uremic pruritus remains one of the most frustrating and potentially disabling symptoms in
      patients with end stage renal disease. It affect up to 90 percent of patients with end stage
      renal disease. Several hypotheses have been postulated for the possible underlying etiology,
      but none is conclusive. Aside from kidney transplantation, which is only definitive
      treatment, therapeutic approaches have largely been empirical, and no firm evident‐base
      treatments are available. The main goal of therapy remains to minimize severity of pruritus.
      In Iranian traditional medicine Cassia senna L. is used for healing uremic pruritus . In this
      study investigators considered to evaluate effect of Cassia senna L. in uremic pruritus by a
      double blind placebo control clinical trial. It is hypothesized that oral Cassia senna L. may
      attenuate uremic pruritus by decreasing serum IL‐2, IFN-γ and TNF‐α.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Pruritis, as measured by a visual analogue scale</measure>
    <time_frame>3 months</time_frame>
    <description>A '0' score represented absence of pruritus and a '10' represented the greatest severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum IL‐2 level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Wheat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Senna</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Senna</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Senna</intervention_name>
    <description>(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day</description>
    <arm_group_label>Senna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet/ 2 times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients

          -  Suffering from pruritus for at least 6 weeks

          -  Have not responded to other drugs

        Exclusion Criteria:

          -  Dermatological disease

          -  Liver disease

          -  Metabolic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdolali Mohagheghzadeh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Mehdi Sagheb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arian Kamali-Sarvestani, Pharm D</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pouya Faridi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Pouya Faridi</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>End stage renal diseases</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Uremic pruritus</keyword>
  <keyword>Iranian traditional medicine</keyword>
  <keyword>Cassia angustifolia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sennoside A&amp;B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

